Alemtuzumab er et genetisk fremstillet humaniseret IgG1 kappa- monoklonalt antistof specifikt for et 21- 28 kD lymfocyt- celleoverfladeglykoprotein (CD 52) udskilt primært på overfladen af normale eller maligne perifere blod B - og T- celle lymfocytter.
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes.